Methods of Treating Gastrointestinal Cancers and Tumors Thereof Using Combination Therapy

Contracts Guide

Disclose Your Invention
MTA/CDA Assistance
COVID-19 Related Agreements
Main Campus Research
Office of Sponsored Research
Education Links

Connect with Industry

Technologies for Licensing
Industry Collaboration Opportunities
Research and Clinical Trials

Categories:  “Cancer Therapeutics

Reference #: 2019-050

OTC Contact: Sharon E. Pula, M.S., J.D. (202) 687-8712 (Directory Information | Send a Message)


A combination therapy method of treating gastrointestinal cancers and tumors thereof in patients with mutations in the homologous recombination-DNA damage response (HR-DDR) pathway genes and/or a family history suggestive of breast or ovarian cancer syndrome through administration of an effective amount of a Poly (ADP ribose) polymerase (PARP) inhibitor, in combination with oxaliplatin and an antimetabolite. The method of the invention also increased the sensitivity of gastrointestinal cancers and tumor cells to treatment with oxaliplatin.


Gastrointestinal cancers and tumors are among the most lethal malignant neoplasms and there is a need for effective treatments for such cancers and tumors as well as the need to increase the sensitivity of such cancers and tumors to existing therapeutic treatments.



Stage of Development

Clinical trials.

Patent Status

Pub. No. US 2022/02111657 A1


Michael J. Pishvaian, MD, PhD

Jonathan Brody, PhD

John L. Marshall, MD, PhD